BioSpace News Archive

Ambrx Biopharma Inc., Ambrx (or the “Company”) (NASDAQ: AMAM), today announced that Daniel J. O’Connor, Chief Executive Officer and President of Ambrx, will participate in a fireside chat and one-on-one meetings at the Cantor Fitzgerald Global Healthcare conference, being held in New York, NY.

Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, “Astellas”) will share new pooled efficacy and safety analyses from the pivotal Phase 3 SKYLIGHT™ studies for VEOZAH™ (fezolinetant), its first-in-class treatment for moderate to severe vasomotor symptoms (VMS) due to menopause, during the 2023 Annual Meeting of The Menopause Society from September 27-30.

Allurion Technologies, Inc. (NYSE: ALUR), a company dedicated to ending obesity, today announced its participation in the 4th International Bariatric Club (IBC) Oxford World Congress, which takes place at Oxford University, September 18-20, 2023.

Enveric Biosciences today announced a poster presentation highlighting novel screening processes and technologies exclusive to Enveric’s EVM301 Series.

Sonendo, Inc. (NYSE: SONX), a leading dental technology company and developer of the GentleWave® System, today announced that management will participate in the upcoming Gilmartin Group Emerging Growth Company Showcase. Management is scheduled to present on Thursday, September 21st at 9:00 a.m. Pacific Time/ 12:00 p.m. Eastern Time.

PharmaEssentia Corporation announced the company is included in the FTSE Global Equity Index Series, FTSE All-World Index, FTSE global All-Cap and total-Cap Indices, and the FTSE Global Mid Cap Index.

Innoviva Specialty Therapeutics, a subsidiary of Innoviva, Inc. (Nasdaq: INVA), today announced that XACDURO® (sulbactam for injection; durlobactam for injection) is now available in the United States for patients 18 years of age and older for the treatment of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia.

Virpax ® Pharmaceuticals, Inc. today announced that it has formed a new wholly-owned subsidiary, Novvae™ Pharmaceuticals, Inc. (Novvae), which has been established to focus exclusively on advancing Virpax’s OTC pipeline.

Humacyte, Inc. (Nasdaq: HUMA), a clinical-stage biotechnology platform company developing universally implantable, bioengineered human tissue at commercial scale, announced it will host an in-person KOL event on Wednesday, September 20, 2023 at 3:00pm ET at The New York EDITION Hotel.

Codexis, Inc., a leading enzyme engineering company, announced Stephen Dilly, MBBS, PhD, President and Chief Executive Officer of Codexis, has been named a finalist for the prestigious 2023 Bloom Burton Award.